报价延迟最少15分钟:2026/08/05 20:06 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.99 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.24/-1.04
|
|
企业价值
308.28M
|
| 资产负债 |
|
每股账面净值
1.64
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
16.10M
|
|
每股收益
0.18
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-usedevices and related services used in patient treatments. |
